IFN-β inhibits the ability of T lymphocytes to induce TNF-α and IL-1β production in monocytes upon direct cell-cell contact

Cytokine

Volumn 14, Issue 5, 2001, Pages 272-282

  Jungo, Florence ^a   Dayer, Jean Michel ^a   Modoux, Christine ^a   Hyka, Nevila ^a   Burger, Danielle ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CONTACT; CELL INTERACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATORY DISEASE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035821606     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0884     Document Type: Article

References (50)

1. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints
2. T-cell-dependent pathways in rheumatoid arthritis
3. Autoimmune pathogenesis of multiple sclerosis: Role of autoreactive T lymphocytes and new immunotherapeutic strategies
4. IFN-gamma and 1, 25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells
5. Cell surface glycoproteins expressed on activated human T-cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
6. Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones
7. Interactions between T cell plasma membranes and monocytes
8. Cell contact-mediated signaling of monocytes by stimulated T cells: A major pathway for cytokine induction
9. Direct contact with stimulated T cells induces the expression of IL-1 beta and IL-1 receptor antagonist in human monocytes. Involvement of serine/threonine phosphatases in differential regulation
10. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells
11. Human Th1 cells preferentially induce interleukin (IL)-1 beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes
12. Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal fibroblasts
13. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: Possible relevance to pathophyslology of rheumatoid arthritis
14. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression
15. The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23
16. Role of the CD40-CD40 ligand interaction in CD4(+) T cell contact-dependent activation of monocyte interleukin-1 synthesis
17. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-alpha production by monocytes and dendritic cells
18. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells
19. Engagement of CD11b and CD11c beta2 integrin by antibodies or soluble CD23 induces IL-1 beta production on primary human monocytes through mitogen-activated protein kinase-dependent pathways
20. Imbalance between interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
21. Direct cell/cell contact with stimulated T lymphocytes induces the expression of cell adhesion molecules and cytokines by human brain microvascular endothelial cells
22. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
23. Treatment of multiple sclerosis with interferon beta
24. The effects of interferon beta treatment on arthritis
25. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy
26. Type I interferons (IFN-alpha and-beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell
27. Interferon-heta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis
28. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis
29. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment
30. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta 1a
31. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients
32. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients
33. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells
34. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment
35. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
36. Interferon-beta not only inhibits interleukin-1 beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells
37. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b
38. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia
39. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers
40. Beta-interferon and multiple sclerosis
41. Effects of an anti-IL-10 monoclonal antibody on rIFN beta-1b-mediated immune modulation. Relevance to multiple sclerosis
42. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors
43. Interleukin-10
44. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1β production in human monocytes and neutrophils
45. Immunosuppressive and anti-inflammatory properties of interleukin-10
46. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis
47. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis
48. Mitogen requirements for the in vitro propagation of T-cell lymphomas
49. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
50. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases